Literature DB >> 16786033

Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease.

I J Martins1, E Hone, J K Foster, S I Sünram-Lea, A Gnjec, S J Fuller, D Nolan, S E Gandy, R N Martins.   

Abstract

High fat diets and sedentary lifestyles are becoming major concerns for Western countries. They have led to a growing incidence of obesity, dyslipidemia, high blood pressure, and a condition known as the insulin-resistance syndrome or metabolic syndrome. These health conditions are well known to develop along with, or be precursors to atherosclerosis, cardiovascular disease, and diabetes. Recent studies have found that most of these disorders can also be linked to an increased risk of Alzheimer's disease (AD). To complicate matters, possession of one or more apolipoprotein E epsilon4 (APOE epsilon4) alleles further increases the risk or severity of many of these conditions, including AD. ApoE has roles in cholesterol metabolism and Abeta clearance, both of which are thought to be significant in AD pathogenesis. The apparent inadequacies of ApoE epsilon4 in these roles may explain the increased risk of AD in subjects carrying one or more APOE epsilon4 alleles. This review describes some of the physiological and biochemical changes that the above conditions cause, and how they are related to the risk of AD. A diversity of topics is covered, including cholesterol metabolism, glucose regulation, diabetes, insulin, ApoE function, amyloid precursor protein metabolism, and in particular their relevance to AD. It can be seen that abnormal lipid, cholesterol and glucose metabolism are consistently indicated as central in the pathophysiology, and possibly the pathogenesis of AD. As diagnosis of mild cognitive impairment and early AD are becoming more reliable, and as evidence is accumulating that health conditions such as diabetes, obesity, and coronary artery disease are risk factors for AD, appropriate changes to diets and lifestyles will likely reduce AD risk, and also improve the prognosis for people already suffering from such conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786033     DOI: 10.1038/sj.mp.4001854

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  117 in total

Review 1.  Role of insulin resistance in Alzheimer's disease.

Authors:  Zhiyou Cai; Ming Xiao; Liying Chang; Liang-Jun Yan
Journal:  Metab Brain Dis       Date:  2014-11-16       Impact factor: 3.584

2.  Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study.

Authors:  Lenore J Launer; Timothy M Hughes; Lon R White
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

3.  Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Edward Re; Lisa Longato; Ming Tong
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

4.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

5.  Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis.

Authors:  M A Beydoun; H A Beydoun; Y Wang
Journal:  Obes Rev       Date:  2008-03-06       Impact factor: 9.213

Review 6.  Relationships between diabetes and cognitive impairment.

Authors:  Suzanne M de la Monte
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

7.  Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adults.

Authors:  Amber S Watts; Natalia Loskutova; Jeffrey M Burns; David K Johnson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 8.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 9.  Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Lisa Longato; Ming Tong; Jack R Wands
Journal:  Curr Opin Investig Drugs       Date:  2009-10

Review 10.  The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease.

Authors:  Xianlin Han
Journal:  Mol Neurobiol       Date:  2010-01-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.